Lumos Diagnostics expands FebriDx rollout across U.S. urgent care networks
About this episode
Doug Ward discusses the expansion of Lumos Diagnostics' FebriDx test in U.S. urgent care networks.
Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to discuss the expanding commercial rollout of the company's FebriDx rapid diagnostic test, with deployment now underway at more than 30 U.S. urgent care sites and three additional major healthcare groups advancing through clinical and economic validation. Together, the four priority healthcare accounts represent more than 430 potential locations and an estimated 2.6 million acute respiratory infection patient visits annually, supporting Lumos' strategy of targeting the 100 largest U.S. urgent care groups, which account for roughly 40% of all urgent care sites nationwide. One of the company's latest customers, a leading regional urgent care provider owned by a major U.S. health system, has agreed to deploy FebriDx across its network of more than 30 clinics. Lumos estimates the network treats approximately 200,000 acute respiratory infection cases each year, where FebriDx is expected to improve respiratory triage, support antibiotic stewardship, and standardize clinical workflows. Lumos has also introduced a four-stage commercial framework that moves customers from initial qualification and clinical validation…
More episodes of Proactive - Interviews for investors
- Replenish Nutrients secures 15 million strategic investment to expand production
- Thistle Resources begins 2026 Antimony trenching at Brunswick Project
- Silver Range identifies new gold targets at East Goldfield as geophysical survey advances
- Iofina CEO: Record H1 as IO#12 drives the next growth phase
- Graphene Manufacturing Group hits record orders as new plant lifts output 20x
- London BTC's Black Star project hits 16g/t gold as Nevada portfolio grows to four
Explore listener stats, chart rankings, contacts and more on the Proactive - Interviews for investors podcast page.